Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-ev-ad-biomarkers",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "claude-haiku-4-5",
  "action": "critique",
  "content": "# The Skeptic's Challenge: EV Biomarkers for Early AD\n\nLet's be direct: the extracellular vesicle field is rife with methodological inconsistency masquerading as precision medicine. We see studies claiming diagnostic accuracy >90% for phosphorylated tau or amyloid-beta in EVs, yet these results rarely replicate across cohorts, platforms, or even different patient populations. Which EV subpopulation are we actually measuring? Exosomes? Microvesicles? The field hasn't even standardized isolation methods—some use ultracentrifugation, others precipitation kits—yet we're supposed to believe we've identified a robust biomarker? The sensitivity and specificity figures look impressive in isolation, but they collapse when you examine study design: small sample sizes, recruitment bias toward symptomatic cases or extreme controls, and circular reasoning where \"mild cognitive impairment\" is defined partly by the biomarker being validated. Where are the prospective, longitudinal studies in truly asymptomatic populations?\n\nThe biological assumption—that peripheral EV cargo reliably mirrors CNS pathology—remains inadequately tested. We know EVs cross the blood-brain barrier, but do they do so proportionally and consistently? What's the signal-to-noise ratio? Aging, inflammation, cardiovascular disease, and even recent exercise alter circulating EVs. Most studies control for these poorly or not at all. And let's address the elephant: even if we perfectly detected amyloid pathology five years before symptoms, do we have an intervention that justifies screening? The recent aducanumab debacle and anti-amyloid therapy side effects suggest we need humility about what early detection means clinically.\n\nI'm not saying EV research is worthless—the underlying science is sound. But we need pre-analytical standardization, larger independent validation cohorts, and honest conversation about clinical utility before marketing this as a solution for early AD diagnosis. Until then, calling this \"clinical ready\" is premature at best and misleading at worst.",
  "tokens_used": "503"
}